Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies
Cancer Medicine · 2025
DOI: 10.1002/cam4.71295 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Medicine, 2025. Verfasst von Fei Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, The First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Epidermal Growth Factor, Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tumor Immunotherapy Academic Special Zone Cultivation Project of the First Hospital of Jilin University, National Natural Science Foundation of China, Science and Technology Department Science and Technology Development Plan Project in Jilin Province.
Abstract (Originalsprache)
Background
Despite multiple clinical trials, the benefits and safety of epidermal growth factor (EGF)/EGF receptor (EGFR) vaccines in EGFR‐driven solid tumors remain unclear due to small sample sizes and heterogeneous study designs. This systematic review and meta‐analysis aimed to evaluate their efficacy and safety.
Methods
We conducted pairwise and single‐arm meta‐analyses following PRISMA guidelines (PROSPERO: CRD420251026774). Searches in PubMed, Embase, and Cochrane Library identified 26 trials (2701 participants). The primary endpoint was overall survival (OS), with secondary analyses of progression‐free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment‐related adverse events (TRAEs). Statistical analyses were performed using R software, with fixed or random‐effects models per heterogeneity ( I 2 ).
Results
Compared with best supportive care, vaccine monotherapy significantly improved long‐term OS in NSCLC and GBM (3‐year OR = 2.16, 5‐year OR = 3.20) and prolonged median OS in NSCLC (HR = 0.76). In single‐arm studies, NSCLC patients receiving vaccine monotherapy had a 1‐year OS of 64% (75% in first‐line maintenance), with an ORR of 2% and DCR of 31%. For GBM, vaccine combination therapy improved 3‐year OS (OR = 2.42) and 2‐year PFS (OR = 1.63) versus standard therapy. Single‐arm combination analyses showed an overall 1‐year OS of 84%, ORR of 42%, and DCR of 87%, while NSCLC first‐line combination achieved a 1‐year OS of 85% and DCR of 89%. Notably, EGFR‐mutant NSCLC patients had a pooled ORR of 65% and DCR of 98%. Common TRAEs were grade 1–2 (injection site reactions, fever, headache, and vomiting), and combination therapy had no new or severe toxicities.
Conclusions
EGF/EGFR vaccines may improve survival in EGFR‐driven solid tumors, particularly NSCLC and GBM. Monotherapy enables long‐term disease control, and combination therapy enhances efficacy without added toxicity, supporting further clinical validation. Trial Registration PROSPERO CRD420251026774
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, The First Hospital of Jilin University, Changchun, China.
- Department of Pathology, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Fei Chen, Jiuwei Cui
Förderung
- Tumor Immunotherapy Academic Special Zone Cultivation Project of the First Hospital of Jilin University
- National Natural Science Foundation of China
- Science and Technology Department Science and Technology Development Plan Project in Jilin Province
- Talent Reserve Program (TRP) at the First Hospital of Jilin University
Zitieren
APA
Chen, F., Bai, L., & Cui, J. (2025). Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies. Cancer Medicine. https://doi.org/10.1002/cam4.71295
Vancouver
Chen F, Bai L, Cui J. Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies. Cancer Medicine. 2025. doi:10.1002/cam4.71295
BibTeX
@article{Chen2025,
author = {Chen, Fei and Bai, Ling and Cui, Jiuwei},
title = {Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71295}
}
EUVIMED